Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first‐line regimen for Helicobacter pylori eradication: A randomized controlled trial

• Published in: Helicobacter (Cambridge, Mass.) Mass.), 2023-02, Vol.28 (1), p.e12935-n/a
• Main Authors: Tian, Xue‐li, Suo, Bao‐jun, Zhang, Hua, Lu, Hao‐ping, Li, Cai‐ling, Zhang, Yu‐xin, Ren, Xin‐lu, Yao, Xing‐yu, Zhou, Li‐ya, Song, Zhi‐qiang
• Format: Article
• Language: English
• Subjects: Amoxicillin; Amoxicillin - adverse effects; Anti-Bacterial Agents - adverse effects; Antibiotics; Bismuth; Bismuth - adverse effects; bismuth quadruple therapy; Compliance; Drug Therapy, Combination; Eradication; Esomeprazole - therapeutic use; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Metronidazole; Metronidazole - adverse effects; Omeprazole; Penicillin; Potassium; Safety; Side effects; tetracycline; Tetracycline - adverse effects; Urea
• ISSN: 1083-4389; 1523-5378
• DOI: 10.1111/hel.12935

Background Due to general unavailability and common side effects of tetracycline, the clinical application of bismuth quadruple therapy (BQT) is greatly limited. Whether amoxicillin can replace tetracycline in BQT remains unknown. This study aimed to compare the eradication rate, safety and compliance between amoxicillin‐containing and tetracycline‐containing BQT as a first‐line regimen for Helicobacter pylori eradication. Methods This randomized trial was conducted on 404 naïve patients for H. pylori eradication. The participants were randomly assigned to 14‐day amoxicillin‐containing (bismuth potassium citrate 110 mg four times/day, esomeprazole 20 mg twice daily, metronidazole 400 mg four times/day and amoxicillin 500 mg four times/day) and tetracycline‐containing (tetracycline 500 mg four times/day and the other three drugs used as above) BQT. Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed 4–8 weeks after eradication to evaluate outcome. Results As for the eradication rates of amoxicillin‐containing and tetracycline‐containing BQT, the results of both intention‐to‐treat and per‐protocol analyses showed that the difference rate of the lower limit of 95% confidence interval was above −10.0% (intention‐to‐treat analysis: 81.7% vs. 83.2%, with a rate difference of −1.5% [−6.3% to 9.3%]; per‐protocol analysis: 89.0% vs. 91.6%, −2.6% [−4.1% to 9.3%]). The incidence of adverse events in amoxicillin‐containing BQT was significantly lower than tetracycline‐containing BQT (29.5% vs. 39.7%). Both groups achieved relatively good compliance (92.0% vs. 89.9%). Conclusion The eradication efficacy of amoxicillin‐containing BQT was non‐inferior to tetracycline‐containing BQT as a first‐line regimen for H. pylori eradication with better safety and similar compliance.